Literature DB >> 2913342

The Cleveland Clinic experience with adrenal cortical carcinoma.

B Bodie1, A C Novick, J E Pontes, R A Straffon, J E Montie, T Babiak, L Sheeler, P Schumacher.   

Abstract

Between 1936 and 1987, 82 patients with adrenal cortical carcinoma were seen at our clinic. Of these patients 49 (72 per cent) have been seen during the last 25 years. A total of 40 patients (48.8 per cent) presented with a hormonally functional tumor and 42 (51.2 per cent) had a nonfunctional tumor. Forty patients (48.8 per cent) presented with localized disease, 12 (14.6 per cent) with regional disease and 30 (36.6 per cent) with distant metastases. Complete surgical removal of all gross tumor was achieved in 49 patients. Over-all 3 and 5-year patient survival rates in this series were 37.5 and 25.1 per cent, respectively. Survival was significantly improved (43.9 per cent at 5 years, p equals 0.0001) in patients with localized disease that was completely removed surgically; postoperative adjuvant therapy with op'-DDD was of no benefit in these patients. Survival in patients with metastatic disease was poor and was not improved by treatment with op'-DDD, cytotoxic chemotherapy or radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913342     DOI: 10.1016/s0022-5347(17)40734-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 4.  Pediatric adrenal cortical carcinoma: brain metastases and relationship to NF-1, case reports and review of the literature.

Authors:  Aaron Scott Wagner; Julie M Fleitz; B K Kleinschmidt-Demasters
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 5.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

6.  Adrenal incidentaloma: a case of carcinoma.

Authors:  Giovanni Ruotolo; Maria Raffaella Ambrosio; Patrizia Rosa Caroleo; Elvira Bonacci; Anna Maria Condito; Alfonso Merante; Pierpaolo Arcuri; Bruno Jim Rocca; Bianca Virginia Palermo; Saverio Palermo; Pietro Gareri
Journal:  Clin Interv Aging       Date:  2010-04-07       Impact factor: 4.458

Review 7.  Nonfunctional adrenal cortical carcinoma. Report of a case and review of the literature.

Authors:  E D Fokaefs; M D Melekos; M P Melachrinou; I E Zarakovitis; G A Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

8.  Adrenocortical carcinoma presenting as bilateral pitting leg oedema.

Authors:  Mohammad Ebrahim Naffaa; Anat Ilivitzki; Eyal Braun
Journal:  BMJ Case Rep       Date:  2014-03-18

9.  Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.

Authors:  Amir H Lebastchi; John W Kunstman; Tobias Carling
Journal:  J Oncol       Date:  2012-10-18       Impact factor: 4.375

Review 10.  Treatment of adrenocortical carcinoma: contemporary outcomes.

Authors:  David Y T Chen; R Ernest Sosa; Douglas S Scherr
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.